Ark Diagnostics

Ark Diagnostics is a commercial-stage diagnostics company with a core focus on homogeneous enzyme immunoassay technology for clinical chemistry analyzers. The company has established a diversified portfolio of ready-to-use liquid assays, primarily serving hospital and reference laboratories for therapeutic drug monitoring and forensic/clinical urine drug testing. Its strategy involves continuous assay development, with recent launches in ethyl glucuronide, ketamine, and methotrexate testing, and a pipeline expanding into areas like veterinary diagnostics and oral anticoagulants. Ark operates globally through a distributor network and maintains a presence at key scientific conferences.

Proprietary homogeneous enzyme immunoassay (HEIA) technology for fully automated clinical chemistry analyzers. Assays are liquid, stable, ready-to-use, and require no separation steps.

Ark Diagnostics competes in niche segments of the broader IVD market dominated by giants like Abbott, Roche, and Siemens. Its competitive edge lies in its specialized focus on homogeneous immunoassays for automated chemistry analyzers, offering a curated menu for TDM and UDT that may not be a priority for larger players. It also faces competition from other specialized assay companies and reference laboratories offering mass spectrometry services.